Skip to main content
. 2021 Aug 27;8:712070. doi: 10.3389/fmed.2021.712070

Figure 2.

Figure 2

Probability of event-free survival (EFS) by Kaplan-Meier estimates in patients with MM treated with VMP (total patients 164). The median EFS was 18.51 mo. VMP, bortezomib plus melphalan-prednisone.